This website uses cookies to ensure you get the best experience on our website.
Privacy Statement
Privacy Statement
patents
In order to foster innovation, HCmed foments intellectual property protection. Our patents include different aspects of our device structure and technologies, including mesh module, breathing sensors, cleaning methods, and wireless authentication systems.
The R&D team of HCmed has developed and patented an innovative technology that allows the aerosolization of different types of medication. This technology works by synchronizing frequency that calibrates the oscillation of the mesh membrane to deliver optimal performance based on the properties of the drug being nebulized.
HCmed’s R&D team works arduously with pharma partners to customize device components and achieve desired outcome. From the careful selection of the mesh membrane to the coding of the driven mechanism, professionals at HCmed provide the most suitable solution for the aerosolization of each formulation.
HCmed’s breath-actuated technology enables aerosolization of medication during inhalation only, avoiding excessive amounts of API being wasted during exhalation. Moreover, it prevents emission of fugitive aerosols that could otherwise be unintendedly inhaled by those surrounding users during their treatment.
HCmed is currently developing a connectivity system and application to link mesh nebulizers to mobile devices. The collected data can be used to monitor and improve patient adherence as well as manage nebulization treatment.
By using the support of connectivity technology, operation of mesh nebulizers can be linked to a specific medication, reinforcing patient adherence. This close system also prevents the use of off-label drugs and controlled substances.
Our APSD laboratory is equipped with state-of-the-art measuring instruments that allow us to conduct aerosol performance analysis. Our team of well-trained researchers meticulously works on generating reliable data in short periods of time to examine drug-device performance. By these means, we are able to support our partners, providing them with analytical services where pretesting of aerosolized formulation does not require GLP compliance. HCmed’s analytical services include aerodynamic particle size distribution analysis, laser diffraction particle size analysis, breath simulation studies, output rate studies, residue studies, and delivered dose studies.
Spraytec laser diffraction particle sizer analyses aerosol particle size distribution in real time.
BRS2100 generates inhalation/exhalation patterns that mimic the breathing of humans. The equipment can be adjusted based on required conditions to fit different ages and conditions.
Lambda 365 allows to check concentration of active pharmaceutical ingredients (API) to better assess drug delivery.
NGI is described as the most efficient way to perform standard in vitro APSD testing. This equipment contains 7 compartments from which 5 of them are in the range 0.5 – 5 microns.
